Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Real-World Use of Biologics and Prescription Topical Medications in a Pediatric Psoriasis Population

Speaker(s)

Swenson A1, Kumparatana P2, Friedler H1, Starzyk K1, Paulus J3
1OM1, Boston, MA, USA, 2OM1, Boson, MA, USA, 3OM1, Dedham, MA, USA

Objectives: A third of psoriasis (PsO) cases report onset during childhood, but few treatments are FDA-approved specifically for use in pediatric patients. The purpose of this analysis was to describe prescription topical and biologic treatment and percent body surface area (%BSA) in a real-world pediatric PsO population.

Methods: Data were derived from the OM1 PsO Registry (OM1, Boston, MA), a multisource real-world registry with linked dermatology EMR data and healthcare claims on US patients with PsO (2013 -2021). All patients aged 4 to <18 years of age at the first observed PsO diagnosis code were included. Follow-up was censored at 18 years. Maximum %BSA and medication use during follow-up were reported. Biologics approved for adult or pediatric PsO in the US were analyzed. Prescription topicals evaluated included corticosteroids, vitamin D analogs, and calcineurin inhibitors.

Results: Of 3,484 pediatric PsO patients identified, 60% were female and mean age at diagnosis was 13 years (SD: 4). Average duration of follow-up was 30 months (SD: 24). 64% of patients were treated with only prescription topicals, 2% were treated with only biologics, and 17% were treated with both. 17% of patients had no record of either treatment. Comorbid inflammatory arthritic/bowel diseases were present in 13% of biologic-treated and 2% of non-biologic-treated patients. Mean maximum %BSA was statistically significantly different based on medication use [10% (SD: 15) in only prescription topicals, 28% (SD: 30) in only biologics, 22% (SD: 24) in both, and 13% (SD:19) in those with no observed prescription treatments, p<0.0001].

Conclusion: Nearly 1 in 5 dermatologist-managed pediatric PsO patients were prescribed biologics before age 18; this population is associated with significantly higher disease burden. Further research is needed to describe the comparative effectiveness of on- and off-label treatments and optimal treatment pathways.

Code

RWD3

Topic

Epidemiology & Public Health, Study Approaches

Topic Subcategory

Electronic Medical & Health Records, Registries, Safety & Pharmacoepidemiology

Disease

Pediatrics